MiR-205-3p suppresses bladder cancer progression via GLO1 mediated P38/ERK activation.
Bladder cancer
GLO1
MiR-205-3p
P38/ERK
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
09 Oct 2023
09 Oct 2023
Historique:
received:
29
12
2022
accepted:
12
07
2023
medline:
11
10
2023
pubmed:
10
10
2023
entrez:
9
10
2023
Statut:
epublish
Résumé
MicroRNAs (miRNAs) have been reported to serve as potential biomarkers in bladder cancer and play important roles in cancer progression. This study aimed to investigate the biological role of miR-205-3p in bladder cancer. We showed that miR-205-3p was significantly down-regulated in bladder cancer tissues and cells. Moreover, overexpression of miR-205-3p inhibited bladder cancer progression in vitro. Then we confirmed that GLO1, a downstream target of miR-205-3p, mediated the effect of miR-205-3p on bladder cancer cells. In addition, we found that miR-205-3p inhibits P38/ERK activation through repressing GLO1. Eventually, we confirmed that miR-205-3p inhibits the occurrence and progress of bladder cancer by targeting GLO1 in vivo by nude mouse tumorigenesis and immunohistochemistry. In a word, miR-205-3p inhibits proliferation and metastasis of bladder cancer cells by activating the GLO1 mediated P38/ERK signaling pathway and that may be a potential therapeutic target for bladder cancer.
Identifiants
pubmed: 37814205
doi: 10.1186/s12885-023-11175-9
pii: 10.1186/s12885-023-11175-9
pmc: PMC10563299
doi:
Substances chimiques
MicroRNAs
0
MIRN205 microRNA, human
0
GLO1 protein, human
EC 4.4.1.5
Lactoylglutathione Lyase
EC 4.4.1.5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
956Subventions
Organisme : National Natural Science Foundation of China
ID : 81702495
Organisme : National Natural Science Foundation of China
ID : 81702495
Organisme : The Key Projects of Natural Science Research Project of Anhui Educational Committee
ID : KJ2021A0706
Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
J Cell Physiol. 2021 Aug;236(8):5620-5632
pubmed: 33687075
Lancet. 2016 Dec 3;388(10061):2796-2810
pubmed: 27345655
Genome Res. 2009 Jan;19(1):92-105
pubmed: 18955434
Development. 2005 Nov;132(21):4653-62
pubmed: 16224045
Dis Model Mech. 2021 Apr 1;14(4):
pubmed: 33973623
Int J Mol Sci. 2018 Jan 31;19(2):
pubmed: 29385039
Cancer Cell. 2020 Apr 13;37(4):543-550
pubmed: 32289276
Cell Rep. 2017 Feb 7;18(6):1543-1557
pubmed: 28178529
Biomed Pharmacother. 2018 Sep;105:461-469
pubmed: 29883941
ACS Chem Biol. 2017 Feb 17;12(2):414-421
pubmed: 27935278
Pathol Res Pract. 2020 Dec;216(12):153257
pubmed: 33142109
Oncotarget. 2017 May 9;8(19):30817-30829
pubmed: 28199217
Mol Med Rep. 2021 Aug;24(2):
pubmed: 34165160
JAMA. 2020 Nov 17;324(19):1980-1991
pubmed: 33201207
J Clin Lab Anal. 2019 Oct;33(8):e22966
pubmed: 31578772
Cancer Manag Res. 2020 Nov 27;12:12205-12214
pubmed: 33273857
FEBS Open Bio. 2020 Oct;10(10):2107-2121
pubmed: 32865871
Medicina (Kaunas). 2021 Jul 24;57(8):
pubmed: 34440955
Int J Clin Exp Pathol. 2014 Apr 15;7(5):2079-90
pubmed: 24966916
Transl Oncol. 2021 Nov;14(11):101199
pubmed: 34388692
Prostate. 2017 Nov;77(15):1528-1538
pubmed: 28929505
Nat Rev Urol. 2013 Jul;10(7):396-404
pubmed: 23712207
Oncol Lett. 2020 Aug;20(2):1743-1751
pubmed: 32724417
Antioxid Redox Signal. 2019 Jan 20;30(3):354-374
pubmed: 29160087
Theranostics. 2019 Oct 18;9(26):8206-8220
pubmed: 31754391
Tokai J Exp Clin Med. 2010 Dec 20;35(4):152-64
pubmed: 21319047
Med Clin (Barc). 2017 Nov 22;149(10):449-455
pubmed: 28736063
Mol Cancer Ther. 2013 Feb;12(2):207-19
pubmed: 23270926
Cell. 2004 Jan 23;116(2):281-97
pubmed: 14744438
Front Plant Sci. 2016 Feb 11;7:80
pubmed: 26904052